Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 2021;23(Suppl_2):i1–105. https://doi.org/10.1093/neuonc/noab200.

Article  Google Scholar 

Cantrell JN, Waddle MR, Rotman M, Peterson JL, Ruiz-Garcia H, Heckman MG, et al. Progress toward long-term survivors of glioblastoma. Mayo Clin Proc. 2019;94(7):1278–86. https://doi.org/10.1016/j.mayocp.2018.11.031.

Article  PubMed  Google Scholar 

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37. https://doi.org/10.1056/NEJMoa1611977.

Article  CAS  PubMed  Google Scholar 

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. https://doi.org/10.1016/S1470-2045(09)70025-7.

Article  CAS  PubMed  Google Scholar 

Garofano L, Migliozzi S, Oh YT, D’Angelo F, Najac RD, Ko A, et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021;2(2):141–56. https://doi.org/10.1038/s43018-020-00159-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. https://doi.org/10.1016/j.ccr.2009.12.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.

Article  PubMed  PubMed Central  Google Scholar 

Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017;49(4):594–9. https://doi.org/10.1038/ng.3806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sa JK, Chang N, Lee HW, Cho HJ, Ceccarelli M, Cerulo L, et al. Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 2020;21(1):216. https://doi.org/10.1186/s13059-020-02140-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. https://doi.org/10.1016/j.cell.2013.09.034.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaitonde SG, Nissan A, Protić M, Stojadinovic A, Wainberg ZA, Chen DC, et al. Sex-specific differences in colon cancer when quality measures are adhered to: results from international, prospective, multicenter clinical trials. J Am Coll Surg. 2017;225(1):85–92. https://doi.org/10.1016/j.jamcollsurg.2017.02.019.

Article  PubMed  Google Scholar 

Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243(5):693–8. https://doi.org/10.1097/01.sla.0000216771.81362.6b.

Article  PubMed  PubMed Central  Google Scholar 

Siegfried JM. Sex and gender differences in lung cancer and chronic obstructive lung disease. Endocrinology. 2022;163:2. https://doi.org/10.1210/endocr/bqab254.

Article  CAS  Google Scholar 

Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero CH. Sex-specific differences in glioblastoma. Cells. 2021;10:7. https://doi.org/10.3390/cells10071783.

Article  Google Scholar 

Kabat GC, Etgen AM, Rohan TE. Do steroid hormones play a role in the etiology of glioma? Cancer Epidemiol Biomark Prev. 2010;19(10):2421–7. https://doi.org/10.1158/1055-9965.Epi-10-0658.

Article  CAS  Google Scholar 

Rodríguez-Lozano DC, Velázquez-Vázquez DE, Del Moral-Morales A, Camacho-Arroyo I. Dihydrotestosterone induces proliferation, migration, and invasion of human glioblastoma cell lines. Onco Targets Ther. 2020;13:8813–23. https://doi.org/10.2147/ott.S262359.

Article  PubMed  PubMed Central  Google Scholar 

Atif F, Yousuf S, Stein DG. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling. J Steroid Biochem Mol Biol. 2015;146:62–73. https://doi.org/10.1016/j.jsbmb.2014.04.007.

Article  CAS  PubMed  Google Scholar 

Hernández-Hernández OT, González-García TK, Camacho-Arroyo I. Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol. 2012;132(1–2):127–34. https://doi.org/10.1016/j.jsbmb.2012.04.005.

Article  CAS  PubMed  Google Scholar 

Atif F, Patel NR, Yousuf S, Stein DG. The synergistic effect of combination progesterone and temozolomide on human glioblastoma cells. PLoS ONE. 2015;10(6):e0131441. https://doi.org/10.1371/journal.pone.0131441.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostrom QT, Rubin JB, Lathia JD, Berens ME, Barnholtz-Sloan JS. Females have the survival advantage in glioblastoma. Neuro Oncol. 2018;20(4):576–7. https://doi.org/10.1093/neuonc/noy002.

Article  PubMed  PubMed Central  Google Scholar 

Broestl L, Warrington NM, Grandison L, Abou-Antoun T, Tung O, Shenoy S, et al. Gonadal sex patterns p21-induced cellular senescence in mouse and human glioblastoma. Commun Biol. 2022;5(1):781. https://doi.org/10.1038/s42003-022-03743-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Liao J, Zhang X, Zhao E, Liang X, Luo S, et al. Sex difference of mutation clonality in diffuse glioma evolution. Neuro Oncol. 2019;21(2):201–13. https://doi.org/10.1093/neuonc/noy154.

Article  CAS  PubMed  Google Scholar 

Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785):112–20. https://doi.org/10.1038/s41586-019-1775-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51. https://doi.org/10.1038/nrneurol.2009.197.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. https://doi.org/10.1038/nature07385.

Article  CAS  Google Scholar 

Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, et al. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell. 2024. https://doi.org/10.1016/j.ccell.2023.12.015.

Article  PubMed  Google Scholar 

Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DI, Zairis S, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016;48(7):768–76. https://doi.org/10.1038/ng.3590.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.

Article  CAS  PubMed  Google Scholar 

Cheung LW, Mills GB. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics. 2016;17(3):297–307. https://doi.org/10.2217/pgs.15.174.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turturro SB, Najor MS, Yung T, Portt L, Malarkey CS, Abukhdeir AM, et al. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019;177(2):325–33. https://doi.org/10.1007/s10549-019-05320-x.

Article  CAS  PubMed  Google Scholar 

Koo H, Choi SW, Cho HJ, Lee IH, Kong DS, Seol HJ, et al. Ethnic delineation of primary glioblastoma genome. Cancer Med. 2020;9(19):7352–9. https://doi.org/10.1002/cam4.3370.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Q, Guan Y, Li Z, Wang Y, Liu Y, Cui R, et al.